Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV

This article was originally published in The Pink Sheet Daily

Executive Summary

The breast cancer diagnostic developer is planning a pivotal trial of its DNA assay to guide chemotherapy in patients by testing disease recurrence. Exagen’s study aims to validate results of a 308-patient trial.

You may also be interested in...



Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle

Zila Medical bypasses lengthy CDER regulatory path, gains 510(k) clearance for ZTC tolonium chloride compound at CDRH. Oral cancer test’s identical compound, OraTest, remains under CDER review.

NQC, Nephros Pursuing Artificial Kidney Through Separate R&D Efforts

National Quality Care plans to file an investigational device exemption within the next few months to begin human studies for a wearable artificial kidney device. Nephros, meanwhile, is conducting Phase II trials of a bioartificial kidney.

Conor Targeting Year-End IDE Submission For Paclitaxel-Eluting Stent

The firm is preparing to submit an investigational device exemption for a pivotal trial supporting a premarket application for its CoStar cobalt chromium stent. However, a market launch could be hindered by intellectual property issues over use of the drug.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel